EGFR and neoplasm: Testa et al. reported a necrotic involution of the tumor and a significant improvement of abdominal pain in a UrC patient who was treated with second-line multikinase inhibitor (Sunitinib) [6], while Goss et al. observed a size regression of a UrC as a response to EGFR-inhibitor therapy with gefitinib (Iressa) [7].